Lishengpharma released its performance for the first three quarters, with a net profit attributable to the parent company of 371 million yuan, a year-on-year increase of 119.05%
According to the Zhitong Finance APP, Lishengpharma disclosed its third-quarter report for 2025. The company achieved a revenue of 1.007 billion yuan in the first three quarters, a year-on-year decrease of 1.61%; the net profit attributable to shareholders of the listed company was 371 million yuan, a year-on-year increase of 119.05%; the net profit excluding non-recurring gains and losses was 127 million yuan, a year-on-year increase of 19.21%; the basic earnings per share were 1.44 yuan
According to the Zhitong Finance APP, Lishengpharma (002393.SZ) disclosed its third-quarter report for 2025. The company achieved a revenue of 1.007 billion yuan in the first three quarters, a year-on-year decrease of 1.61%; the net profit attributable to shareholders of the listed company was 371 million yuan, a year-on-year increase of 119.05%; the net profit excluding non-recurring gains and losses was 127 million yuan, a year-on-year increase of 19.21%; the basic earnings per share were 1.44 yuan
